相关实验视频

Updated: Jan 13, 2026

Author Spotlight: Integrating Alveolar-Capillary Reserve Measurements in Exercise Adaptation and Therapeutic Strategies
08:44

Author Spotlight: Integrating Alveolar-Capillary Reserve Measurements in Exercise Adaptation and Therapeutic Strategies

Published on: February 2, 2024

1.2K

低DLCO可以提供有关PAH患者治疗反应的见解,无论其减少的原因是什么

Effrosyni Dima1, Stylianos E Orfanos2, Vasileios Grigoropoulos1

  • 1Pulmonary Hypertension Center of "Evangelismos" Hospital and 1st Department of Critical Care Medicine and Pulmonary Services, Medical School, National and Kapodistrian University of Athens, "Evangelismos" Hospital, 10676 Athens, Greece.

Life (Basel, Switzerland)
|October 29, 2025
PubMed
概括

肺动脉高血压 (PAH) 中一氧化碳 (DLCO) 扩散能力低的患者是老年人,男性和吸烟者. 这一PAH亚组的预后不佳,对血管扩张疗法的反应有限.

关键词:
在 DLCO 找 DLCO这些PAH是PAH.临床特征 临床特征现象型 现象型 是一种现象型.治疗治疗治疗治疗治疗治疗

更多相关视频

Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis09:13

Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis

Published on: January 5, 2024

1.9K
Using Laser Doppler Imaging and Monitoring to Analyze Spinal Cord Microcirculation in Rat09:28

Using Laser Doppler Imaging and Monitoring to Analyze Spinal Cord Microcirculation in Rat

Published on: May 30, 2018

10.5K

相关概念视频

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
3.1K
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
346
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
580
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.7K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
548